Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims align with the provided label excerpts for topical corticosteroids (indication, dosing frequency/application as a thin film by strength, occlusive dressing guidance, and infection-related precautions). However, it does not fully evaluate several safety-relevant label elements that were included in the provided excerpts (notably contraindications, boxed warning status, and adverse reactions), limiting completeness.
Category Scores
Accurate Statements
Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Section 1 INDICATIONS AND USAGE: “Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.”
They are generally applied as a thin film two to four times daily for 0.025% strength and two or three times daily for 0.1% and 0.5% strength depending on severity.
Section 2 DOSAGE AND ADMINISTRATION: “...thin film two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity...”
Occlusive dressings may be used for management of psoriasis or recalcitrant conditions.
Section 2 DOSAGE AND ADMINISTRATION: “Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.”
If an infection develops, occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Section 2 DOSAGE AND ADMINISTRATION: “If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.”
Systemic absorption can produce reversible HPA-axis suppression and related findings, and conditions that augment absorption include more potent steroids, large surface areas, prolonged use, and occlusive dressings.
Section 5 WARNINGS AND PRECAUTIONS (systemic absorption): “Systemic absorption... has produced reversible HPA axis suppression... Conditions which augment systemic absorption include... and the addition of occlusive dressings.”
In the presence of dermatological infections, use an appropriate antifungal or antibacterial agent; if no prompt favorable response, discontinue the corticosteroid until infection is adequately controlled.
Section 5 WARNINGS AND PRECAUTIONS: “…use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.”
Unsupported Statements
“Boxed warning present: Not evaluated/Not shown in provided excerpts.”
The excerpt set provided by the user did not include a boxed warning section, so the statement is not supported as a conclusion about whether a boxed warning exists; it is only a meta-evaluation. It is therefore unsupported as a factual claim regarding boxed warning presence.
“Contraindications present: Not evaluated/Not shown in provided excerpts.”
The user-supplied label excerpts include a contraindications section (Section 4). Therefore, stating contraindications were “Not evaluated/Not shown in provided excerpts” is unsupported relative to the materials provided.
“Pregnancy risk: Not assessed (no relevant labeling excerpt provided).”
The user did not provide pregnancy-specific excerpts, so this is not directly verifiable; however it is not a label-claim mismatch. It is unsupported only as a determination about label coverage rather than what is actually present.
“Pediatric safety: Not assessed (no relevant labeling excerpt provided).”
Same limitation as above: pregnancy/pediatric-specific excerpts were not provided, so the statement is not supported as a determination; but it does not contradict the label excerpts.
Contradictions
Low
AI Statement
“Contraindications present: Not evaluated/Not shown in provided excerpts.”
Label Reference
Section 4 CONTRAINDICATIONS was included in the user-supplied label excerpts: “Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity...”
Important Omissions
Contraindications were included in the provided excerpts but were not evaluated in the assessment narrative (e.g., hypersensitivity contraindication).
Importance:
Moderate
Local adverse reactions list (burning, itching, irritation, dryness, etc.) was included in the provided excerpts but was not evaluated in the assessment narrative.
Importance:
Moderate
Boxed warning status was not assessed with respect to the provided excerpt set (no boxed warning excerpt shown).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core clinical safety-related elements explicitly addressed (infection/occlusion guidance and systemic absorption warning) are consistent with the supplied label excerpts. The main gaps relate to completeness of evaluation (contraindications, adverse reactions) rather than incorrect dosing/precautions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incomplete evaluation of safety label elements that were provided (contraindications and adverse reactions) and meta-statements that contradicted what was included (contraindications not evaluated/not shown).
Suggested Improvement
Explicitly evaluate and cite the provided contraindications (Section 4) and the provided local adverse reactions list (Section 6). Avoid stating that contraindications were “not shown” when they are present in the provided excerpts.